Pharmaceutical giant MSD announces 330 jobs in Carlow and Cork
There is a huge employment boost for Carlow and Cork this morning as pharmaceutical giant MSD announce 330 jobs. The roles, which span across technical, engineering, biochemistry, biology, quality and operations, are part of a €280 million investment from the company.
MSD, which is known as Merck in the UK and Canada, employs over 1,600 people across four sites in Ireland – Carlow, Cork, Dublin and Tipperary.
Commenting on the investment, Jobs Minister Mary Mitchell O’Connor said that she “warmly welcomed” the announcement.
“MSD has been at the cutting edge of bio pharmaceutical innovation over recent years and their Irish operations are at the heart of many of the company’s exciting new products,” she said.
The plant in Brinny, Co. Cork is for the development, testing and manufacturing of biologics, specialising in the fermentation, purification and sterile filling of biotech products. 200 new staff will work on this site, developing medicines for lung cancer, melanoma, hepatitis C and rheumatoid arthritis. In Carlow, 120 jobs will be created in the state-of-the-art manufacturing facility.
The company said its two manufacturing sites in Cork and Carlow are important links in its global chain of plants. It said it was making the investment as a result of increased global demands in its Ireland manufactured medicines and vaccines.
“The announcement by MSD of further investment and expansion of their Irish Biopharma sites in Cork and Carlow is superb news and a vote of confidence in the quality of graduates from the Irish Universities”
Ken Murphy, Director of CareerWise Recruitment
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world’s most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit www.msd.com and connect with us on Twitter.